



Grant Confirmation

- 1. This **Grant Confirmation** is made and entered into by **the Global Fund to Fight AIDS, Tuberculosis and Malaria** (the "Global Fund") and **Hindustan Latex Family Planning Promotion Trust** (the "Principal Recipient" or the "Grantee"), pursuant to the Framework Agreement, dated as of 21 December 2023, as amended and supplemented from time to time (the "Framework Agreement"), between the Global Fund and the Grantee, to implement the Program set forth herein. The Grant Confirmation is effective as of the earlier of the start date of the Implementation Period (as defined below) or the date of the Global Fund's signature below, and Program Activities shall not commence prior to the start date of the Implementation Period, unless otherwise agreed in writing by the Global Fund.
- Single Agreement. This Grant Confirmation, together with the Integrated Grant 2. Description attached hereto as Schedule I, sets forth the provisions (including, without limitation, policies, representations, covenants, Program Activities, Program budget, performance framework, and related implementation arrangements) applicable to the Program, and forms part of the Grant Agreement. Each capitalized term used but not defined in this Grant Confirmation shall have the meaning ascribed to such term in the Framework Agreement (including the Global Fund Grant amended from time to time). available Regulations (as at https://www.theglobalfund.org/media/5682/core grant regulations en.pdf). In the event of any inconsistency between this Grant Confirmation and the Framework Agreement (including the Global Fund Grant Regulations (as amended from time to time)), the provisions of this Grant Confirmation shall govern unless expressly provided for otherwise in the Framework Agreement.

3.1	Host Country or Region:	Republic of India
3.2	Disease Component:	HIV/AIDS, Tuberculosis
3.3	Program Title:	SSHAKTI: Strategizing and Strengthening HIV/AIDS & TB Intervention
3.4	Grant Name:	IND-C-HLFPPT
3.5	GA Number:	3899
3.6	Grant Funds:	Up to the amount of USD 25,151,509 or its equivalent in other currencies
3.7	Implementation Period:	From 1 April 2024 to 31 March 2027 (inclusive)
3.8	Principal Recipient:	Hindustan Latex Family Planning Promotion Trust

3. **<u>Grant Information</u>**. The Global Fund and the Grantee hereby confirm the following:

		B-14A, IInd Floor, Sector-62, Noida Gautam Budh Nagar Uttar Pradesh 201307 Gautam Budh Nagar Republic of India Attention: Mr. AJAY JHA Associate National Lead- Finance Email: <u>akjha@hlfppt.org</u>
3.9	Fiscal Year:	1 April to 31 March
3.10	Local Fund Agent:	Price Waterhouse LLP Building 8, 8th Floor, Tower-B DLF Cyber City 122002 Gurgaon Republic of India Attention: Heman Sabharwal Team Leader Telephone: +911244620148 Facsimile: +91-124-462-0620 Email: <u>heman.sabharwal@pwc.com</u>
3.11	Global Fund contact:	The Global Fund to Fight AIDS, Tuberculosis and Malaria Global Health Campus, Chemin du Pommier 40 1218 Grand-Saconnex, Geneva, Switzerland Attention: Urban Weber Department Head Grant Management Division Telephone: +41-587911700 Facsimile: +41-445806820 Email: urban.weber@theglobalfund.org

- 4. **Policies**. The Grantee shall take all appropriate and necessary actions to comply with (1) the Global Fund Guidelines for Grant Budgeting (2023, as amended from time to time), (2) the Health Products Guide (2018, as amended from time to time), and (3) any other policies, procedures, regulations and guidelines, which the Global Fund may communicate in writing to the Grantee, from time to time.
- 5. **Covenants**. The Global Fund and the Grantee further agree that:

5.1 The procurement of Health Products shall be carried out through the Pooled Procurement Mechanism ("PPM") of the Global Fund, unless the Global Fund directs the Principal Recipient otherwise in writing. The Principal Recipient has all the necessary power and authority to execute, deliver and carry out its obligations under the wambo.org – PPM registration letter in the form approved by the Global Fund.

5.2 External Auditor

(1) Grant Funds may be used to pay for the services of an external auditor retained by the Global Fund for the annual independent audit of the Program (the "External Auditor") and the Global Fund may disburse such Grant Funds directly to the External Auditor;

(2) The Principal Recipient consents, to the carrying out of audits of the Program by the External Auditor for the period covering fiscal years 2024-2025, 2025-2026 and 2026-2027 (and other such additional periods as the Global Fund may communicate to the Principal Recipient in writing), and to the terms of reference of the External Auditor and agrees that such terms of reference may be amended from time to time; and

(3) Without limiting Section 7.5 of the Global Fund Grant Regulations (as amended from time to time), the Principal Recipient shall cooperate fully with the External Auditor to allow the External Auditor to perform its services, including by providing all information and documents requested by the External Auditor or the Global Fund.

5.3 Prior to the use of Grant Funds in Budget Lines 432 and/or 433, and no later than 31 March 2025, the Principal Recipient shall submit in form and substance satisfactory to the Global Fund, and obtain the Global Fund's written approval of the following:

(1) For Budget Line 432, a reprogramming request prepared in coordination with the National AIDS Control; and

(2) For Budget Line 433, a reprogramming request prepared in coordination with the Central TB Division.

(3) If the conditions set forth in Section 5.3 and 5.3(1) and/or 5.3(2), respectively, are not met by 31 March 2025, the funds in the respective Budget Line may be reprogrammed in accordance with this Grant Agreement.

[Signature Page Follows.]

IN WITNESS WHEREOF, the Global Fund and the Grantee have caused this Grant Confirmation to be executed and delivered by their respective duly authorized representatives on their respective date of signature below.

The Global Fund to Fight AIDS, Tuberculosis and Malaria

Hindustan Latex Family Planning Promotion Trust

By: MA. Elden Edy C By: Name: Mark Eldon-Edington Name: Sharad Agarwal Head, Grant Management Title: Title: Chief Executive Officer Division 21st Harch 2024. Date: Mar 29, 2024 Date:

Acknowledged by

Ву: _____

Name: Apurva Chandra

Title: Chair, Country Coordinating Mechanism of Republic of India Date:

By:

Name: Anandi Yuvaraj

Title:

Civil Society Representative, Country Coordinating Mechanism of Republic of India

Date:

27/03/24

Schedule I

Integrated Grant Description

A. PROGRAM DESCRIPTION

1. Background and Rationale for the Program

In accordance with the Sustainable Development Goals (SDG), India is committed to "End the AIDS epidemic as a public health threat by 2030" through comprehensive prevention, detection and treatment services. India's efforts towards the prevention and control of HIV/AIDS have been globally acclaimed. The country has been successful in declining the annual new HIV infections by 42% and reduced the annual AIDS-related deaths by nearly 77% from 2010 to 2022.

Despite significant successes, vulnerable populations such as adolescents, at-risk youth, incarcerated persons at prisons and other close settings and pregnant women continue to be disproportionately affected. Of the estimated 24.67 lakh PLHIV in India, 79% PLHIV were aware of their HIV status. Among them, 86% were on ART and the viral load suppression was at 93% among on-ART PLHIV. In terms of comprehensive knowledge of HIV/AIDS, there are gaps among the population. As per the findings of National Family Health Survey Phase 5 (NFHS V), only one-fifth (22%) of women and nearly one-third of men (31%) age 15-49 in India have comprehensive knowledge of HIV/AIDS.

The Ministry of Health & Family Welfare, Government of India developed a National Strategic Plan 2017-25 (NSP 2017-25) aimed to achieve 80% reduction in TB incidence and 90% reduction in deaths by 2025. In 2022, 30% notification were reported from by the private sector while in 2023 it was 34%. Additional efforts are needed to bridge the gap and increase both the private and public sector notification.

The National TB Elimination Program (NTEP) reiterates that a multipronged approach is required to detect the missing cases through active and passive case finding, treatment and follow up of diagnosed cases to End TB. Active Case Finding (ACF) has shown to increase the case notification which leads to reduction in the burden of TB in terms of both mortality and morbidity. As per NSP 2017-25, focus of ACF prioritizes key and vulnerable population (KVP) in identified targeted geographies. Prioritizing the urban slums, industry workers and prison inmate for ACF can support finding the missing TB cases and mitigate the impact of TB in both the prison environment and the broader community.

In India, the lack of rapid and prompt diagnoses in low-resource settings with high endemicity poses a major constraint on DR-TB treatment. In 2022, there was still a gap in diagnosis of RR/MDR-TB cases in India resulting in further transmission of DR strains in the community. There were 5,82,332 Extra pulmonary TB cases notified in 2022, of which 3,63,483 (62%) samples went through molecular (NAAT) testing whereas 2,18,850 (38%) EPTB cases were left without microbiological confirmation of the diagnosis.

Informal health care providers are often the first point of contact for a significant proportion of TB patients in rural areas/ semi-urban settings due to factors related to accessibility and affordability. Therefore, engagement of informal providers is critical to bring these TB patients within the ambit of NTEP.

Efficient and accurate sample collection and transportation are essential components of a robust diagnostic system, especially for diseases like tuberculosis (TB). The adoption of a barcode system can significantly enhance the traceability, tracking, and quality of samples throughout the testing process.

To strengthen the National efforts of NACP-V and NTEP objectives, and bridge the gaps, Hindustan Latex Family Planning Promotional Trust (HLFPPT) as principal recipient with support of other partners is implementing the next GFATM grant cycle (GC7) from April 2024 to March 2027 in more than 400 districts across 17 States in India.

2. Goals

- Overall goals of the project have been aligned with the objectives of NACP and NTEP in achieving the following:
- Elimination of vertical transmission of HIV and Syphilis.
- Promoting universal access to quality HIV, STI/RTI and TB services to at-risk, vulnerable populations and infected population.
- Improved comprehensive knowledge on HIV/AIDS.
- Elimination of stigma and discrimination related to HIV/AIDS and TB.
- Decrease mortality and morbidity due to TB and cut transmission of infection until TB ceases to be a major public health problem.

Strategies

To achieve the goals, the project envisaged the following strategies:

1. Promote and facilitate viral suppression among PLHIV and ensuring that LFU cases return to treatment and care.

2. Build the capacity of the network of PLHIV/HRG/Bridge population along with CBOs to increase case detection and treatment adherence and eliminating stigma and discrimination.

3. Scaling up interventions for HIV, TB, STIs, and Hepatitis B & C in incarcerated populations at prisons, and other close settings.

4. Enhance awareness on HIV/AIDS among the general population and youth to foster a stigma and discrimination free inclusive environment through Red Ribbon Bus (RRB) campaign.

5. Active Case Finding for early detection of TB cases among vulnerable population including the prison inmates.

6. Scaling up of upfront NAAT testing for Paediatric TB & EP TB Specimen to bridge the gap in testing.

7. Strengthen the existing system of DRTB patient management and linkages to TB treatment services in the private sector.

8. Engagement of AYUSH and Informal provider to increase the access of standard TB care.

9. Collaboration with corporate chain of hospitals and Labs for quality TB treatment and care.

10. Addressing Stigma & Discrimination through Skilling of TB Survivors/Champions.

11. Technical assistance to strengthen sample collection and transportation using a barcode system to streamline the diagnostic process, reduce errors, and improve the overall quality of TB diagnosis and treatment.

Planned Activities

A. <u>Care and Support Centre (2.0)</u> – this intervention will be implemented in 252 districts across 12 states and following activities will be conducted: Facilitate early initiation of ART for all newly diagnosed PLHIV; Track and recover lost to follow-up, ensuring their return to treatment and care; Support PLHIV enrolled in ART to achieve viral suppression including positive pregnant women (during the 32-36 week of pregnancy) and those on 2nd and 3rd line treatment regimens; Ensure virological testing for all HIV-exposed infants within six weeks of birth, and ensure comprehensive infant diagnosis at the 6th months; Effective linkage of syphilis-positive Pregnant Women (PW) and syphilis-exposed children to appropriate treatment and care.

B. <u>Community System Strengthening</u> – this intervention will be implemented in 252 districts across 12 states and following activities will be conducted: Training of Community Champions and CLM Model Integration; Enhancing community capacities and State Level Network (SLN); Facilitation of District Community Resource Group.

C. <u>Prison and OCS Intervention</u> – this intervention will be implemented in 366 districts across 15 states and following activities will be conducted; Promoting holistic health awareness: empowering incarcerated communities with focus on HIV, STI and TB; Empowering and enhancing capabilities of prison peer volunteers and health care providers; Increase STI, HIV, and TB testing among incarcerated populations; Link the post-release PLHIV inmates with DLNs and CSC 2.0.

D. <u>Red Ribbon Bus</u> – This campaign will be implemented in 15 states and following activities will be conducted: Microplanning of campaign in consultation with NACP (at National, State and District level); Running a campaign on HIV awareness through Red Ribbon Bus; Mobilization, IEC, counselling, screening and referral at halting points.

E. <u>Active Case Finding in urban slums, prison inmates and other vulnerable population</u> – this intervention will be implemented in 76 districts across 7 states and following activities will be conducted: Outreach activities for TB screening of key and vulnerable population for PTBP identification; comprehensive health camp for TB testing by using handheld Xray machine and referral for TB testing and diagnosis.

F. Lab strengthening for scaling up of UPFRONT NAAT testing for Paediatric TB & EP TB <u>Specimen</u>– this intervention will be implemented in 30 districts across 5 states and following activities will be conducted: Laboratory preparedness & building capacity of the existing NTEP labs for the processing of paediatric specimen types such as gastric lavage, BAL, induced sputum, lymph node aspirates, etc. for use in NAAT; Establishment of Hub by linking local facilities with the labs for testing and scale up of linkages with the hub; District level provider engagement through CMEs. ; Capacity building for specimen collection for technicians & providers. *G.* <u>Strengthen DRTB patient management in Private Sector</u> - this intervention will be implemented in 30 districts across 5 states and following activities will be conducted: Capacity assessment of the facilities on standard parameter for DRTB case management; Establishment of Hub as DRTB patient management; Technical support to the hubs and spokes for upgrading their facilities as per the need assessment; Capacity building of health staff on DRTB patient management as per NTEP guidelines.

H. <u>Engagement of AYUSH and Informal provider</u> - this intervention will be implemented in 36 districts in three states and following activities will be conducted: Sensitization and engagement of AYUSH & informal providers on NTEP guidelines; Encourage AYUSH and non-traditional health care providers to establish referral and linkage with govt. health facilities; Provision for availing informant & treatment supporter incentive for AYUSH & Informal providers will be encouraged.

I. <u>Engagement of Corporate Chain of Hospitals and Labs</u>: under this intervention 150 chain of hospital and labs pan Indian will be engaged and following activities will be conducted: Advocacy with corporate hospital & lab, state, districts NTEP and other stakeholders; Development of engagement model; Engagement of the hospitals and advocacy with corporate hospitals, lab & NTEP/STC; Negotiation and leverage for subsidized costing of diagnosis, upfront DST and provisioning of Government FDC and reagents.

J. <u>Skilling of TB Survivors/ Champions</u> –under this intervention technical support will be provided in the 6 states by conducting following activities: Linking of TB survivors/ champions to course for skill development; Ensure the course completion and placement.

K. <u>Technical assistance in Strengthening the SCT</u>– will be provided to 76 districts across 7 states and following activities will be conducted: Training of NTEP staff on barcode system implementation for sputum collection and transportation; Technology adoption and linking it to the patient's information; Quality assurance and feedback.

HLFPPT will leverage the PPSA program to get additional support to implement TB related intervention.

3. Target groups / Beneficiaries

PLHIV, positive pregnant women, HIV exposed infants, spouse and partners of PLHIV, PLHIV on 3rd line treatment, people in prison and other close settings, high risk groups (FSW,MSM,H/TG, PWID), key and vulnerable population (urban slum, construction worker, industries worker), TB survivors, youth and general population.

B. PERFORMANCE FRAMEWORK

Please see attached.

C. SUMMARY BUDGET

Please see attached.

Country	India
Grant Name	IND-C-HLFPPT
Implementation Period	01-Apr-2024 - 31-Mar-2027
Principal Recipient	Hindustan Latex Family Planning Promotion Trust

Reporting Periods	Start Date	01-Apr-2024	01-Oct-2024	01-Apr-2025	01-Oct-2025	01-Apr-2026	01-Oct-2026
	End Date	30-Sep-2024	31-Mar-2025	30-Sep-2025	31-Mar-2026	30-Sep-2026	31-Mar-2027
	PU includes DR?	No	Yes	No	Yes	No	No

Program Goals, Impact Indicators and targets

1	Reduce annual new HIV infections by 80%
2	Eliminate vertical transmission of HIV and Syphilis
3	Eliminate HIV/AIDS related stigma and discrimination
4	Promote universal access to quality STI/RTI services to at-risk and vulnerable populations
5	Achieve a rapid decline in burden of TB, morbidity and mortality to achieve the Sustainable Development Goals of 80% reduction in incidence and 90% reduction in deaths by 2025; five years

i mortality to elopm 5 earlier of the global targets aity a

	Impact Indicator	Country	Baseline Value	Baseline Year and Source	Required Dissagregation	2024	2025	2026
1	HIV I-4 Number of AIDS-related deaths per 100,000 population	India	N: 2.8900 D: P: %	2022 Global AIDS Monitoirng, 2022	Gender,Age,Gender Age	N: D: P: % TBD Due Date:	N: D: P: % TBD Due Date:	N: D: P: % TBD Due Date:
	Comments							
	Baseline # N - 39624 Baseline # D - 1371733204 Value - 2.89 and updated in year 1.	The indicator will be r	eported by NACO on an	annual basis. The targe	ets will be set by NACO	-		
2	HIV I-14 Number of new HIV infections per 1000 uninfected population	India	N: 0.0500 D: P: %	2022 Global AIDS Monitoirng, 2022	Gender,Gender Age,Age	N: D: P: % TBD Due Date:	N: D: P: % TBD Due Date:	N: D: P: % TBD Due Date:
	Comments		1	1				
	Baseline # N - 66408 Baseline # D - 1369266204 Value - 0.05 and updated in year 1.	The indicator will be r	eported by NACO on an	annual basis. The targe	ets will be set by NACO	_		
3	HIV I-6 Estimated percentage of children newly infected with HIV from mother-to-child transmission among women living with HIV delivering in the past 12 months	India	N: 4128.0000 D: 20735 P: 19.91%	2022 Global AIDS Monitoirng, 2022		N: D: P: % TBD Due Date:	N: D: P: % TBD Due Date:	N: D: P: % TBD Due Date:
	Comments	l	<u> </u>	<u> </u>				
	Baseline # N - 4128 Baseline # D - 20735 Percentage (%) - 19 NACO and updated in year 1.	.91 The indicator will b	e reported by NACO or	an annual basis. The ta	rgets will be set by	-		


Program Objectives, Outcome Indicators and targets

1 95% of people who are most at risk of acquiring HIV infection use comprehensive prevention

2 95% of HIV positive know their status, 95% of those who know their status are on treatment and 95% of those who are on treatment have suppressed viral load

Performance Framework







3 95% of pregnant and breastfeeding women living with HIV have suppressed viral load towards attainment of elimination of vertical transmission of HIV

- 4 Less than 10% of people living with HIV and key populations experience stigma and discrimination
- 5 Early identification and access to treatment for preventing loss of disability-adjusted life years from TB and reducing costs incurred by TB patients

Outcome Indicator	Country	Baseline Value	Baseline Year and Source	Required Dissagregation	2024	2025	2026				
HIV O-11 Percentage of people living with HIV who know their HIV status at the end of the reporting period	India	N: 1948635.0000 D: 2467000 P: 78.99%	2023 Sankalak Fifth Edition, 2023 (Pg # 153)	Gender Age,Age	N: D: P: 91.00% Due Date: 30-May-2025	N: D: P: 95.00% Due Date: 30-May-2026	N: D: P: 95.00% Due Date: 30-May-202				
Comments											
ooninicht3			This indicator is to be reported by NACO. Baseline # N - 1948635 Baseline # D - 2467000 Value - 79% Perodicity: The indicator will be reported by NACO on an annual basis. Target Assumption: The targets defined for these indicators are as per NACP -V Strategy Document Pg # 42. Numerator: Number of								
This indicator is to be reported by NACO. Baseline # N - 1948	or these indicators are a										
This indicator is to be reported by NACO. Baseline # N - 1948 on an annual basis. Target Assumption: The targets defined fo	or these indicators are a number of PLHIV				N: D: P: 93.00%	N: D: P: 94.00%	N: D: P: 95.00%				
This indicator is to be reported by NACO. Baseline # N - 1948 on an annual basis. Target Assumption: The targets defined fo PLHIV who know their HIV Status Denominator: Estimated n HIV O-12 Percentage of people living with HIV and on ART	or these indicators are a number of PLHIV	N: 1009262.0000 D: 1084218	2023 Sankalak Fifth Edition, 2023 (Pg #	nerator: Number of	N: D:	D:	D:				

Payment for results grant. Numerator: Number of people living with HIV on ART for at least 6 months and with at least one routine VL test result who have virological suppression (<1000 copies/mL) during the reporting period. Denominator: Number of people living with HIV on ART for at least 6 months with at least one routine VL result during the reporting period. Viral load testing coverage will also be reported in by NACO. The PR should provide an update on the viral load testing coverage to vaildate this indicator.

Coverage i	ndicators and targets													
CI Number	Coverage Indicator	Country and Scope of Targets	Baseline Value	Baseline Year and Source	Required Dissagregation	Include in GF Results	Cumulation Type	Reverse Indicator	01-Apr-2024 30-Sep-2024	01-Oct-2024 31-Mar-2025	01-Apr-2025 30-Sep-2025	01-Oct-2025 31-Mar-2026	01-Apr-2026 30-Sep-2026	01-Oct-2026 31-Mar-2027
Differentiated	HIV Testing Services													
1	HTS-3f Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results	Country: India; Coverage: Geographic Subnational, less than 100% national program target	N: 675702 D: P: %	2023 Num : Data Source: SANKALAK 5th Edition, 2023 (Pg# 81 & 153)	Gender	Yes	Non cumulative	No	N: 474459 D: P: %	N: 474459 D: P: %	N: 533767 D: P: %	N: 533767 D: P: %	N: 593074 D: P: %	N: 593074 D: P: %
	Comments													
	Indicator and target has been align 6,75,702. Data Source: Sankalak who know their status Target: Wh and 100% in third year, and has b will be carried out as per actual no	2022-23 Programme actu ile baseline for this indic een calculated basis num	al measure: Numerator ator was 57% out of th ber of inmates target co	- Number of people in p e denominator of inmate overage given by NACO	orisons and other closed s from Sankalak 2022-2 for the year 2023-24. (1	settings who have b 23, the target has bee	een tested for HIV duri en kept at 80% in first y	ng the reporting period an ear, 90% in the second year	id ai					
2	HTS-3e Percentage of other vulnerable populations that have received an HIV test during the reporting period and know their results	Country: India; Coverage: Geographic Subnational, less than 100% national program target	N: 20397 D: 55142 P: 36.99%	2023 Num : Sankalak V Edition 2023 Den : Sankalak V Edition 2023		Yes	Non cumulative	No	N: D: P: 55.00%	N: D: P: 55.00%	N: D: P: 65.00%	N: D: P: 65.00%	N: D: P: 75.00%	N: D: P: 75.00%
	Comments				-			-						

Advance Control Interaction Contro Interaction C	CI Number		Country and		Baseline Year	Required	Include in GF			01-Apr-2024	01-Oct-2024	01-Apr-2025	01-Oct-2025	01-Apr-2026	01-Oct-20
Image: Set in the build of the set in the set		Coverage Indicator		Baseline Value		-		Cumulation Type	e Reverse Indicator					30-Sep-2026	31-Mar-20
Impact of a vertical function of a VPV specific and particle in the proof	2	been sourced from Sankalak V E 2023. Spouse/ partner testing of I Source – Project MIS/ referral reg (30328/55142 for both reporting information: The eligibility criter received test result. Spouse/ partn on the actual list of PLHIV share Considering spouse/ partner who Achiement of first PU1 is subject data would be used to report Num	dition 2023 which is 55, HIV positive people iden gister Denominator - Nur periods S1 and S2) in Y1 ria will be followed durin ners of registered client w d during the project impl would require HIV testin t to Care and Support Cei	147. and nemerator (Nu ntified- 20,397 keeping t mber of spouses and sev 1, 65% (35842/55142 in ng index client registrati will be referred to ICTC lementation by ART cer ng @ twice the number inter transition plan (Oth	mber of spouses and sex he baseline at 37%. Nur ual partners due for HIV S3 and S4) in Y2 and 7 on in CRF section B The for HIV test. The eligib tters. Spouse/Partner wh of total PLHIV identifie er PR to HLFPPT). Free	ual partners screened for herator - Number of spou 7 testing (after 1 year of 5% (41357/55142 in S5 e indicator captures the n lity will be determined b o already tested positive d, hence the denominato puency- Bi- annually Dur	HIV during the re- lises and sexual part ART initiation) dur and S6) in Y3. (Sou umber of spouse/ p based on the list sha and know the result r has been calculator ring the Progress U	porting period) has been iners tested for HIV duri- ring the reporting period arce: Client registration partners of PLHIV refer- ared by ART center. This it will be excluded from ed based on the same use pdate reporting to Globa	sourced from Sankalak-V ng the reporting period Targets are set at 55% form) Source of ed for HIV testing and s will be calculated based the denominator. Target: ed for baseline source al Fund, actual programme	e					
Image: space of the space	mination of		syphilis and hepatitis	В											
No. N															
Control Number of the second spectra with NNO patients in SNO Next (130) Dependence 3.300 Next (140) Figure 3.400 Patients in SNO Patient in SNO Patients in SNO Patient in SNO Patients in SNO		exposed infants tested for HIV at	Coverage: Geographic Subnational, less than 100% national	D: 3906 P: 84.74%	2023 BSD MPR/SOCH		No	Non cumulative	No		D:	D:	D:		N: D: P: 100.00%
1 Interpretent pretent p	5	Comments													
3 Source of the second sec		under EID cascade during the rep Period Source: BSD MPR/SOCH in S1 and S2), Year2 - 95% (185: months. Taget for this indicator in (Target Year1 - 95%, Year2 and	borting Period. Source: B I/PMTCT Program Data 5/1953 in S3 and S4) and s Year1 - 92%, Year2-95	BSD MPR/SOCH/PMTC Project will report the 9 d Year3 - 100% (1953/1 5% and Year3-100% Pro	T Program Data Denon 6 of HIV-exposed infan 953 in S5 and S6) For th ject will also report the	inator: No. of HEI eligit s receiving a virological is indicator, denominato % of HIV-exposed infan	ble for 6-months test test for HIV withir r will only include ts receiving a virol	sting under EID cascade a 6 months of birth Targe live births and exclude i ogical test for HIV with	during the reporting et Year1 - 92% (1797/195) nfant deaths within 6 in 2 months of birth	3					
TCS Object-Levening of Public values and the program integral Description Program integral Provide Program integral No	atment, ca	re and support													
Comments Indicator and target has been aligned with NSP and NACO guidance. Baseline: Baseline has been sourced from SOCH 2021-22 and 2022-23. Denominator - Number of LFU cases reported in AKT MPRSOCH funit to proceeding years. And the momentario - Number of LFU cases inaded with definite outcome ⁺ during the reporting period One of the priority outcash intervention shares and the momentario - Number of LFU cases inaded with definite outcome ⁺ during the case (a loce) - give for HLV related services. This indicator expresses interaction in the case (b H classes) to encounce interations in AFT cases. Are specific and the momentario - Number of LFU: PLW view of HLFU cases reported in AKT cases and the case in the case of the line of the case of the specific and the case of the line of the case of the case of the momentario - Number of LFU: PLW view of the case of th		PLHIV on ART who are Lost to Follow up (LFU) tracked back	Coverage: Geographic Subnational, less than 100% national	D: 1842 P: 43.49%	2023 SOCH, NACO		No		No		D:	D:			N: D: P: 98.00%
3 Indicator and target has been algred with NSP and ARCO guidance. Baccline: Baccline has been sourced from SOCI 1201:22 and 2022-32. Denominator - Number of LPC cases reported in ART - intervention is to contailer PLM by in the community to minimize the Last to Follow Up cases, ensure ART ART enter or time the protring period. The protring period. The control is to container PLM by in the community to minimize the Last to Follow Up case, ensure ART ART enter or time the protring period. The contable LPT velocited start events the set with difficient container events to a start test the set of the priority period. The contable LPT velocited start events to ensure transment in follow up of PLT PLW on ART Win the contable LPT velocited start events the set with difficient container to ARX period. The priority period test the velocited in the priority period. The contable LPT velocited start events the event to introduce the priority period. The contable LPT velocited start events the event to introduce the priority period. The contable LPT velocited start events the event to event the relation of the priority to velocities. The programme Letter velocities are velocities and the priority of the priority to velocities. The programme Letter velocities and the priority to velocities. The programme Letter velocities and the priority of the priority to velocities. The programme Letter velocities and the priority to velocities. The programme Letter velocities and the priority to velocities. The programme Letter velocities and the priority to velocities. The priority to Velocities and the priority to velocities and the priority to velocities. The priority and the priority to velocities and the priority to velocities. The priority definities and the priority to velocities and the priority to velocities and the priority to velocities. The priority definities of the priority to velocities and the priority to velocities and the priority to velocities and the priority to velocitie		Commonte	program target												
4 N: 138914 D: 000000000000000000000000000000000000		MPR/SOCH from two preceding composite intervention is to conta This indicator captures the outcon complete address, treatment reter cases at ART centers through out contact or ARV pick-up for 90 da	years. And the numerator act PLHIV in the commu- me information on traceantion and adherence are the treach with definite outcor ays or more since last due	or - Number of LFU cas unity to minimize the Lo able LFU clients list reco the most crucial activitie ome as per the line list r e date (missed appointn quate ounselling) and pr	es tracked with definite st to Follow Up cases, e eived from ART centers s in composite intervent eceived from ART center ent). Opted out: If a PL ovides in writing about	outcome* during the rep- nsure ART adherence, ti to ensure treatment in A ion programme activities rs. Programme Definitio HIV is contacted through the same, outcome of the	orting period One of mely referral for C RT center during th s. The programme a ns- On ART lost to a outreach (home vi s visit will be report	of the priority outreach in D-4 test and follow-up f ne reporting period. Trace aims to track back all ali of follow up (LFU): PLHI isit) and expresses his/he ted as 'opted out' in the f	ntervention strategies under or HIV related services. eable clients are with we and contactable LFU IV on ART with no clinicater or unwillingness to						
4N: NoN: N: NoN: N:<	3	another visit through project coor attempts by CSC/ART centre to a medicines shall also be considered treatment should be documented (or any other document, which ca death certificate or a valid docum ready to give their contact details of the same over phone and docu centre under the national program ART. After confirmation of trans "transferred in."" Numerator: Nu brought back to ART center, Clie preceding years. Targets are set a The target for this indicator has b Frequency- Bi- annually During to calculated based on the SOCH ar will be calculated based on actua	rdinator/peer counsellor of retrieve patient back and ed as "Opted Out" Stoppe in white card. Died: If de an prove the death) is pro- nentation is not available, s for verification by ART ument on white card (e.g. n to another. However, P sfer by recipient ART cer umber of LFU cases track ents taking ART from oth at 70% (645/921 in S1 an been calculated based on the Progress Update repond same denominator has 1 data received from SOC	of CSC should be attem resolve the reason for n ed treatment: PLHIV on eath of a patient is confi ovided then upon submis , documentation can be ' centre. If outreach is no date of death, probable PLHIV will be labelled a ntre, the parent ART cent ked back to ART Centre her ART centers and fro ad S2) in Y1, 85% (783/ the same denominator up orting to Global Fund, ac s been used as the baseli CH/ ART MPR. Achiev	beted. Such patients would ot continuing ART serv. ART whose treatment is rmed by family member asion of the same, it could be possible and family member reason of death). Transf s 'transferred out' only we tre will change status in with definite outcome of member Private sector). Deno 221 in S3 and S4) in Y2 sed in baseline Achiemed that programme data we ne and numerator has be	d be labelled as "Opted 0 ces under national progr s stopped on medical adv s/relatives/local authoriti d be updated in white ca orkers/CSC staff in writir ember/relative, declare d erred out: Transferred ou when patient reaches reci their MLL/IMS as "tran luring the reporting perior ninator: Number of LFU and 98% (903/921 in S5 ent of first PU1 is subject buld be used to report Nu en calculated based on ta	Out" in white card amme. Patients tak vice (in discussion view es during outreach rd/MLL/IMS as "d ag either from the view leath over phone, m at refers to a situation pient ART centre a sferred out" and the d. (Definite outcom cases reported in A and S6) in Y3. So to Care and Suppo- umerator and Denon arget. During project	and IMS/MLL, at least a ing treatment from priva with the clinical team). T and valid documentatio eath" by the data manag illage headman or close hedical officer of the AR on when a patient seeks and transfer has been acc e receiving ART centre nes will include Opted C ART MPR during the pe urce: ART MPR (3.8)/ S ort Center transition plan minator. Target for this i ct implementation both c	ces. If not reachable, after 3 documented the or taking alternate The reasons for stopping n such as death certificate er of ART centre. In case family members who are T centre shall take details transfer from one ART repted in IMS by recipient will label this patient as Dut, Death, transfer out and riod and past two OCH Target Calculation: a (Other PR to HLFPPT). ndicator has been lenominator and numerato	d					
than 100% national program target	3	another visit through project coor attempts by CSC/ART centre to a medicines shall also be considered treatment should be documented (or any other document, which ca death certificate or a valid docum ready to give their contact details of the same over phone and docu centre under the national program ART. After confirmation of trans "transferred in."" Numerator: Nu brought back to ART center, Clie preceding years. Targets are set a The target for this indicator has b Frequency- Bi- annually During to calculated based on the SOCH ar will be calculated based on actua	rdinator/peer counsellor of retrieve patient back and ed as "Opted Out" Stoppe in white card. Died: If de an prove the death) is pro- nentation is not available, for verification by ART ment on white card (e.g. n to another. However, P sfer by recipient ART cer imber of LFU cases track ents taking ART from oth at 70% (645/921 in S1 an been calculated based on the Progress Update repo- nd same denominator has data recived from SOG	of CSC should be attem resolve the reason for n ed treatment: PLHIV on eath of a patient is confi ovided then upon submis , documentation can be ' centre. If outreach is no date of death, probable PLHIV will be labelled a ntre, the parent ART cent ked back to ART Centre her ART centers and fro ad S2) in Y1, 85% (783/ the same denominator up orting to Global Fund, ac s been used as the baseli CH/ ART MPR. Achiev	beted. Such patients would ot continuing ART serv. ART whose treatment is rmed by family member asion of the same, it could be possible and family member reason of death). Transf s 'transferred out' only we tre will change status in with definite outcome of member Private sector). Deno 221 in S3 and S4) in Y2 sed in baseline Achiemed that programme data we ne and numerator has be	d be labelled as "Opted 0 ces under national progr s stopped on medical adv s/relatives/local authoriti d be updated in white ca orkers/CSC staff in writir ember/relative, declare d erred out: Transferred ou when patient reaches reci their MLL/IMS as "tran luring the reporting perior ninator: Number of LFU and 98% (903/921 in S5 ent of first PU1 is subject buld be used to report Nu en calculated based on ta	Out" in white card amme. Patients tak vice (in discussion view es during outreach rd/MLL/IMS as "d ag either from the view leath over phone, m at refers to a situation pient ART centre a sferred out" and the d. (Definite outcom cases reported in A and S6) in Y3. So to Care and Suppo- umerator and Denon arget. During project	and IMS/MLL, at least a ing treatment from priva with the clinical team). T and valid documentatio eath" by the data manag illage headman or close hedical officer of the AR on when a patient seeks and transfer has been acc e receiving ART centre nes will include Opted C ART MPR during the pe urce: ART MPR (3.8)/ S ort Center transition plan minator. Target for this i ct implementation both c	ces. If not reachable, after 3 documented the or taking alternate The reasons for stopping n such as death certificate er of ART centre. In case family members who are T centre shall take details transfer from one ART repted in IMS by recipient will label this patient as Dut, Death, transfer out and riod and past two OCH Target Calculation: a (Other PR to HLFPPT). ndicator has been lenominator and numerato	d					
Comments	3	another visit through project coor attempts by CSC/ART centre to a medicines shall also be considered treatment should be documented (or any other document, which ca death certificate or a valid docum ready to give their contact details of the same over phone and docu centre under the national program ART. After confirmation of trans "transferred in."" Numerator: Nu brought back to ART center, Clie preceding years. Targets are set a The target for this indicator has b Frequency- Bi- annually During to calculated based on the SOCH ar will be calculated based on actua Nagaland, Odisha, Rajasthan, Sik TCS-8 Percentage of people living with HIV and on ART with	rdinator/peer counsellor of retrieve patient back and ed as "Opted Out" Stoppe in white card. Died: If de an prove the death) is pro- nentation is not available, s for verification by ART ment on white card (e.g. n to another. However, P. sfer by recipient ART cer imber of LFU cases track ents taking ART from oth tt 70% (645/921 in S1 an been calculated based on the Progress Update repo- nd same denominator has l data received from SOO ckim, Tripura, West Beng Country: India; Coverage: h Geographic Subnational, less than 100% national	of CSC should be attem resolve the reason for n ed treatment: PLHIV on eath of a patient is confi ovided then upon submis , documentation can be ' centre. If outreach is no date of death, probable PLHIV will be labelled a ntre, the parent ART cert ked back to ART Centre her ART centers and fro id S2) in Y1, 85% (783/ the same denominator u orting to Global Fund, ac s been used as the baseli CH/ ART MPR. Achiev gal, Uttar Pradesh N: 138914 D: 385548 P: 36.03%	ART whose treatment is rmed by family members sion of the same, it could be possible and family members of possible and family members of possible and family members is 'transferred out' only y tre will change status in with definite outcome of member Private sector). Deno 221 in S3 and S4) in Y2 sed in baseline Achiemed true and numerator has be ement will be reported b	d be labelled as "Opted 0 ces under national progr s stopped on medical adv s/relatives/local authoriti d be updated in white ca orkers/CSC staff in writir ember/relative, declare d erred out: Transferred ou when patient reaches reci- their MLL/IMS as "tran luring the reporting perior ninator: Number of LFU and 98% (903/921 in S5 ent of first PU1 is subject buld be used to report Nu en calculated based on ta y project MIS Intervention	Out" in white card amme. Patients tak vice (in discussion v tes during outreach rd/MLL/IMS as "d ag either from the v leath over phone, m it refers to a situation pient ART centre and sferred out" and the vd. (Definite outcom cases reported in 2 and S6) in Y3. Sout to Care and Suppo- umerator and Denois arget. During projecton states: Arunacha	and IMS/MLL, at least a ing treatment from priva with the clinical team). T and valid documentatio eath" by the data manag illage headman or close hedical officer of the AR on when a patient seeks and transfer has been acc e receiving ART centre mes will include Opted C ART MPR during the pe urce: ART MPR (3.8)/ S ort Center transition plan minator. Target for this i ct implementation both o al Pradesh, Assam, Bihar	ces. If not reachable, after 3 documented the or taking alternate The reasons for stopping n such as death certificate er of ART centre. In case family members who are T centre shall take details transfer from one ART repted in IMS by recipient will label this patient as Dut, Death, transfer out and riod and past two OCH Target Calculation: (Other PR to HLFPPT). ndicator has been lenominator and numerator r, Delhi, Meghalaya,	d N: D:	D:	D:	D:		N: D: P: 95.00%

lumber	Coverage Indicator	Country and Scope of Targets	Baseline Value	Baseline Year and Source	Required Dissagregation	Include in GF Results	Cumulation Type	Reverse Indicator	01-Apr-2024 30-Sep-2024	01-Oct-2024 31-Mar-2025	01-Apr-2025 30-Sep-2025	01-Oct-2025 31-Mar-2026	01-Apr-2026 30-Sep-2026	01-Oct-20 31-Mar-20
4	Indicator and target has been alig source -SOCH Denominator - Nu S3 and S4), Year3- 95% (181135 3rd line ART completing 6 mont Year2- 80%, Year3- 95% Newly 85%, Year2 - 90%, Year3 -95% 1	Imber of people living wi /192774 in S5 and S6) A hs of treatment" PPW due initiated on 3rd line ART	th HIV on ART for at l chievement will be seg e for VL test at 32-36 w completing 6 months	east six months, source regrated on - "Positive p reeks As per SOCH 202 of treatment As per SOC	ng with HIV on ART w -SOCH Target is Year1 pregnant woman (PPW) 3 Numerator is 889 and CH 2023 Numerator is 2	- 75% (144581/1927 due for viral load (V denominator is 5,22 57 and denominator	774 in S1 and S2), Year2 7L) test at 32-36 weeks" 26. Achievement was 179 5 is 388. Achievement is 6	2- 85% (163858/192774 in and "newly initiated on 6 Target is Year1- 60% , 56% Target is Year1 -	1					
agnosis,	treatment and care		····· , ···· ,				(, , , , , , , , , , , , , , , , , , ,							
		Country: India;												
9	TBDT Other-1: Number of extrapulmonary TB patients and pediatric samples tested	Coverage: Geographic Subnational, less than 100% national program target	N: D: P: %			No	Non cumulative	No	N: D: P: %	N: 4500 D: P: %	N: 10800 D: P: %	N: 10800 D: P: %	N: 12600 D: P: %	N: 12600 D: P: %
9	Comments		1											
	This is a new intervention for the HUB lab centres for testing EPTI EPTB samples which had underg cases. Each hub Lab will be testin Considering 1/2 of these labs wil	B and pediatric samples u one NAAT testing were ng a total of 50 EPTB and	sing NAAT testing. Ar only 1,28,000 thus, 50% l Pediatric samples per	ound 2,50,000 EPTB ca 6 of the EPTB cases we month during the 1st ye	ses were reported amon re not even offered NAA ear, 60 sample per month	gst the five proposed AT test. Assuming 3 in the 2nd year & 7	d states during the year 2 0 hubs will be able to cat 70 samples in the 3rd yea	022. At the same time , er nearly 15-20% EPTB r in its full capacity.						
id vulne	rable populations (KVP) – TB/I	DR-TB												
	KVP-1 Number of people with TB (all forms) notified among prisoners; *includes only those with new and relapse TB	Country: India; Coverage: Geographic Subnational, less than 100% national program target	N: D: P: %			Yes	Non cumulative	No	N: 70 D: P: %	N: 157 D: P: %	N: 165 D: P: %	N: 165 D: P: %	N: 189 D: P: %	N: 189 D: P: %
6	Comments	program target												
	KVP-2 Number of people with TB (all forms) notified among key affected populations/high risl groups (other than prisoners); *includes only those with new and relapse	Subnational, less than 100% national	N: D: P: %			Yes	Non cumulative	No	N: 1110 D: P: %	N: 2649 D: P: %	N: 4193 D: P: %	N: 4193 D: P: %	N: 4544 D: P: %	N: 4544 D: P: %
	Comments	program target												
7	Active case finding will be done house 4S screening and health ca district per month) Baseline: The worker), this is a new interventio (other than prisoners) Denominat mapped for 4S screening - 1,32,1 Camp - Urban slums, unorganize expected 76 NTEP districts (58 b will be selected in consultation w achivement by project MIS which	mps for testing of PTBP re is no baseline data for n sites and not currently to or - Not applicable Hous 6,153 (80%), 4S Screenind d labour, stone crusher w y HLFPPT and 18 by Do ith NTEP. Target may be	in urban slums, at consi ACF in proposed key v racked by the national e to House Campaign - ng done - 1,18,94,538, (orker, weaving and ind ctors for You) will be c e revisit after one year b	truction sites and indust ulnerable population (u TB programme Numera Urban slums Estimated (90%), PTBP identified ustry worker, constructi covered in the 7 state na	ry In 58 district being ir rban slums, construction tor - Number of people urban slum population - 5,94,727 (5%), Tested ton sites 2 health camp p mely Uttar Pradesh, Ma	nplemented by HLF, a worker, urorganize with TB (all forms) - 1,65,20,191 (Source for TB - 4,75,782 (Source for district per month harashtra, Bihar, Od	PPT comprehensive heal d labour, stone crusheras notified among key popu ce : Census of India), vul 80%), Diagnosed for TB h will be conducted and 6 lisha, Chhattisgarh, Gujar	th camp is proposed (2 pe a, and glass industry dlations/ high risk groups nerable population - 14,273 (3%) Health 5,960 TB notification is rat and Rajasthan. District						
resistant	: (DR)-TB diagnosis, treatment	and care												
	DRTB-2 Number of people with confirmed RR-TB and/or MDR- TB notified	Country: India; Coverage: Geographic Subnational, less than 100% national program target	N: D: P: %		HIV status,Gender,Age	Yes	Non cumulative	No	N: D: P: %	N: 220 D: P: %	N: 420 D: P: %	N: 420 D: P: %	N: 645 D: P: %	N: 645 D: P: %
8	Comments		1					1						
	This is a new intervention for the Hub centres for DRTB targeting reported to have drug resistance a nearly 2986 cases in the private s	the private sector. There as per the NAAT test among	are 3.87 lakh TB notific ongst these geographies	cations from these geograming of these only 3,202 DF	raphies annually from pr RTB cases were notified	ivate sector. A total from private sector.	of 6,188 TB cases from (As per India TB report	the private sector were 2023) Thus, a gap of						

Workplan Tracking Measures

workplan Tracking	Ivicasules								
Intervention	Key Activity	Milestones	Criteria for Completion	Country				01-Apr-2026 30-Sep-2026	
Collaboration with other p	providers and sectors								
Community-based TB/DR-TB care	Operational research study to assess the outcome of engagement of AYUSH and informal practitioners for TB awareness, 4S Screening and referral of presumptive case	Data collection of referral per study protocol	0 - Not started 1 - Started: 30% data collected 2 - Advanced: 70% of data collected 3 - Completed: 100% data collected and ready to be analyzed	India		x			
		Development of concept note for operational research study	0 - Not started 1 - Started: Draft concept note developed 2 - Advanced: Final concept note developed and shared with GF for comments 3 - Completed: Concept note finalized, approved by Ethics Board	India	x				
	for TB testing	Report writing and dissemination	0 - Not started 1 - Started: Draft report developed 2 - Advanced: Final report developed and shared with stakeholders for comments 3 - Completed: Report finalized and disseminated	India			Х		

Comments

The project aims to cover 1000 AYUSH practitioners and unorganised providers for engaging in TB awareness, 4S screening and referral for public health action 43,500 presumtive cases will be referred by engaged AYUSH for public health action

Prevention package for other vulnerable populations (OVP)

Prevention package for ot	iner vulnerable populations							
		Hiring and branding of red ribbon bus	0 - Not started 1 - Started: Bids issued 2 - Advanced: Final contract being negotiated 3 - Completed: Final contract signed	India	х			
	Red Ribbon Bus will run in	Percentage of states covered by red ribbon bus as per microplan in PU2 for the reporting period	0 - Not started 1 - Started: 20% of states being covered 2 - Advanced: 40% of states being covered 3 - Completed: more than 50% of states being covered	India		х		
HIV prevention	15 states for enhancing awareness among youth, women and adolecent; fostering an inclusive awareness from from	Percentage of states covered by red ribbon bus as per microplan in PU3 for the reporting period	0 - Not started 1 - Started: 20% of states being covered 2 - Advanced: 40% of states being covered 3 - Completed: more than 50% of states being covered	India			х	
and demand creation for OVP	environment, free from stigma and discrimination; raising awareness about the HIV & AIDS (Prevention and Control) Act, 2017, and	Percentage of states covered by red ribbon bus as per microplan in PU4 for the reporting period	0 - Not started 1 - Started: 20% of states being covered 2 - Advanced: 40% of states being covered 3 - Completed: more than 50% of states being covered	India				х
	Helpline Number 1097	Percentage of states covered by red ribbon bus as per microplan in PU5 for the reporting period	0 - Not started 1 - Started: 20% of states being covered 2 - Advanced: 40% of states being covered 3 - Completed: more than 50% of states being covered	India				
		Percentage of states covered by red ribbon bus as per microplan in PU6 for the reporting period	0 - Not started 1 - Started: 20% of states being covered 2 - Advanced: 40% of states being covered 3 - Completed: more than 50% of states being covered	India				

Comments

Red Ribbon Bus (RRB) will cover selected district as per micro plan Prevalent rate will be criteria and 69 moderate prevalent districts as per "District level HIV Estimates and Prioritisation in India 2019, NACO"

Х

Country	India
Grant Name	IND-C-HLFPPT
Implementation Period	01-Apr-2024 - 31-Mar-2027
Principal Recipient	Hindustan Latex Family Planning Promotion Trust

By Module	Total Y1 - 2025	Total Y2 - 2026	Total Y3 - 2027	Grand Total	% of Grand Total
Collaboration with other providers and sectors	\$266,663	\$305,161	\$292,257	\$864,081	3.4 %
Drug-resistant (DR)-TB diagnosis, treatment and care	\$789,145	\$579,187	\$347,281	\$1,715,613	6.8 %
Key and vulnerable populations (KVP) – TB/DR-TB	\$441,074	\$467,429	\$1,056,799	\$1,965,301	7.8 %
Prevention package for other vulnerable populations (OVP)	\$363,953	\$222,702	\$274,569	\$861,225	3.4 %
Prevention package for people in prisons and other closed settings	\$728,009	\$708,099	\$606,025	\$2,042,132	8.1 %
Program management	\$1,370,988	\$1,761,968	\$1,319,732	\$4,452,688	17.7 %
Removing human rights and gender related barriers to TB services	\$30,997	\$61,994	\$61,994	\$154,984	0.6 %
RSSH: Community systems strengthening	\$276,939	\$243,012	\$65,732	\$585,683	2.3 %
RSSH: Monitoring and evaluation systems	\$409,767	\$393,493	\$378,954	\$1,182,213	4.7 %
TB diagnosis, treatment and care	\$899,637	\$948,388	\$882,896	\$2,730,921	10.9 %
Treatment, care and support	\$2,077,441	\$2,621,173	\$3,898,054	\$8,596,668	34.2 %
Grand Total	\$7,654,612	\$8,312,604	\$9,184,292	\$25,151,509	100.0 %

By Cost Grouping	Total Y1 - 2025	Total Y2 - 2026	Total Y3 - 2027	Grand Total	% of Grand Total
1.Human Resources (HR)	\$3,755,473	\$4,923,635	\$6,451,854	\$15,130,962	60.2 %
2.Travel related costs (TRC)	\$2,361,073	\$2,644,601	\$2,144,959	\$7,150,633	28.4 %
3.External Professional services (EPS)	\$939,719	\$99,914	\$99,914	\$1,139,547	4.5 %
5.Health Products - Non-Pharmaceuticals (HPNP)	\$16,773	\$71,048	\$35,178	\$122,999	0.5 %
6.Health Products - Equipment (HPE)		\$132,009	\$12,001	\$144,010	0.6 %
8.Infrastructure (INF)	\$149,317	\$9,227	\$9,227	\$167,771	0.7 %
9.Non-health equipment (NHP)	\$307,048	\$75,599	\$69,683	\$452,330	1.8 %
10.Communication Material and Publications (CMP)	\$26,518	\$28,617	\$4,199	\$59,334	0.2 %
11.Indirect and Overhead Costs	\$51,714	\$280,978	\$310,301	\$642,994	2.6 %
13.Payment for Results	\$46,977	\$46,977	\$46,977	\$140,930	0.6 %
GrandTotal	\$7,654,612	\$8,312,604	\$9,184,292	\$25,151,509	100.0 %

By Recipients	Total Y1 - 2025	Total Y2 - 2026	Total Y3 - 2027	Grand Total	% of Grand Total
PR	\$3,596,274	\$3,626,380	\$5,446,438	\$12,669,091	50.4 %
HINDUSTAN LATEX FAMILY PLANNING PROMOTION TRUST	\$3,596,274	\$3,626,380	\$5,446,438	\$12,669,091	50.4 %
SR	\$4,058,338	\$4,686,225	\$3,737,855	\$12,482,418	49.6 %
Doctors For You (DFY)	\$1,474,634	\$1,675,767	\$1,334,556	\$4,484,957	17.8 %
HL SR1	\$1,091,085	\$1,287,138	\$891,446	\$3,269,669	13.0 %
HL SR2	\$713,253	\$813,796	\$671,102	\$2,198,152	8.7 %

Summary Budget



By Recipients	Total Y1 - 2025	Total Y2 - 2026	Total Y3 - 2027	Grand Total	% of Grand Total
HL SR3	\$779,367	\$909,523	\$840,751	\$2,529,640	10.1 %
Grand Total	\$7,654,612	\$8,312,604	\$9,184,292	\$25,151,509	100.0 %
Source Of Funding	Total Y1 - 2025	Total Y2 - 2026	Total Y3 - 2027	Grand Total	% of Grand Total
Source Of Funding Approved Funding				Grand Total \$25,151,509	